|
Patent landscape, scope, and claims: |
Scope and Claims Analysis for US Patent 10,646,484 (Buprenorphine 1x Monthly Subcutaneous LA/GA Polymer Depot in Injection-Drug Patients)
US 10,646,484 is a method-of-treatment patent centered on a specific once-per-month subcutaneous buprenorphine depot composition and its therapeutic use in injection-drug patients with moderate-to-severe opioid use disorder (OUD). The core commercial “hook” is a defined formulation scaffold: ~300 mg buprenorphine free base in a high N-methyl-2-pyrrolidone (NMP) vehicle plus a poly(DL-lactide-co-glycolide) (PLGA) copolymer (including a carboxy-terminated, ~9,000 to ~19,000 Da, 50:50 variant) for controlled release. The claims mix (i) treatment duration (at least six or at least twelve months) and (ii) clinical endpoints (abstinence, craving, withdrawal, illicit opioid use), but they also remain tightly anchored to the same composition ranges and administration schedule.
H1: US 10,646,484 Claims for Once-Per-Month Subcutaneous Buprenorphine Depot in Injection-Drug Patients
What is the exact claim scope of US 10,646,484 and what is the “infringement core”?
Infringement core (composition + administration + patient + OUD severity):
- Route and frequency: subcutaneous administration once per month.
- Treatment duration: at least six months (independent claim 1) or at least twelve months (dependent claims 2 and 11).
- Patient population: an injection drug patient (independent claims 1 and 4; claim 19 further enumerates IV/IM/subcutaneous injection-drug patients).
- Drug substance form: buprenorphine free base, ~300 mg.
- Formulation identity: a buprenorphine composition comprising:
- (i) ~300 mg buprenorphine free base at a specified wt % (notably 18 wt % in claim 1 and 10).
- (ii) PLGA copolymer with specific chemistry and molecular weight windows (in claim 1: 50:50 PLGA, carboxy terminal group, ~9,000 to ~19,000 Da; wt % ~32%).
- (iii) N-methyl-2-pyrrolidone at ~50 wt %.
- Therapeutic target and outcome language: treatment of moderate-to-severe OUD (claim 1) and/or OUD broadly (claim 4 and its dependents include severity-specific forms). Independent claim 4 plus dependents recite outcomes like abstinence, craving, withdrawal symptoms, and illicit opioid use reduction/elimination.
Practical scope effect: Even where downstream dependents broaden endpoint language (craving, withdrawal, illicit use), the patent remains a composition-tethered method. A challenger would typically need to change at least one hard anchor: monthly subcutaneous schedule, patient classification, free base dose, NMP proportion, PLGA type (50:50 vs broader), carboxy-terminal requirement, and/or molecular weight, or the specific wt % composition within the recited windows.
Claim-by-claim consolidation (what each group actually adds)
Independent claim set (two “composition-defined” method claims):
- Claim 1: Once-monthly SC dosing for ≥6 months in injection-drug patients with moderate-to-severe OUD, using a high-specificity composition:
- buprenorphine free base: ~300 mg at 18 wt %
- 50:50 PLGA (carboxy terminal; ~9,000–19,000 Da) at ~32 wt %
- NMP at ~50 wt %
- Claim 4: Similar method (once-monthly SC; ≥6 months; injection-drug patients; buprenorphine composition includes free base + PLGA + NMP) but not locked to the claim-1 exact PLGA molecular weight and carboxy-terminated specification in its preamble. Claim 4 still sets the “composition concept,” while later dependents lock narrower PLGA/NMP/PLGA wt% bands.
Duration dependents (manufacturing-to-commercial alignment):
- Claim 2: at least twelve months (depends from claim 1 scope).
- Claim 11: at least twelve months (depends from claim 4 scope).
Endpoint dependents (intended to map to clinical trial claims and labeling concepts):
- Claims 3, 12: “produces opioid abstinence” in injection drug users.
- Claims 13–18: craving and withdrawal (reduce/eliminate) and illicit opioid use (reduce/eliminate), tied to claim 4’s method frame.
Severity dependents (OUD severity becomes an easy design-around target if accused product targets only one severity tier):
- Claims 5–7: moderate, severe, moderate-to-severe in claim 4 lineage.
- Claims 21–23: moderate, severe in claim 20 lineage.
- Claim 1 already fixes moderate-to-severe.
Route-of-injection dependent (patient definition breadth):
- Claim 19: injection drug patient includes intravenous, intramuscular, or subcutaneous injection-drug patients. This matters because “injection drug patient” can otherwise be fact-disputed.
Composition bands inside the claim set (how “narrow” is narrow?)
Across dependents, the PLGA and NMP content ranges are expanded to broader windows, but still anchored by:
- buprenorphine free base around 300 mg, and
- NMP in a large fraction (30–70 wt % ranges appear repeatedly), and
- PLGA within defined copolymer identity windows (50:50 up to 95:5 and wt % 10–60), with molecular weight windows.
Key dependent “locks” include:
- Claim 10 (and mirrors claim 1): repeats claim-1 composition: 18 wt% buprenorphine; 32 wt% 50:50 carboxy-terminated PLGA at ~9,000–19,000 Da; 50 wt% NMP.
- Claims 8–9: broader PLGA wt% (10–60 or 22–42), broader PLGA MW windows (5,000–40,000; or 5,000–30,000) and broader PLGA lactide:glycolide ratios (50:50 to 95:5; or 50:50 to 80:20), with NMP 30–70 or 40–60.
- Claims 24–28 and 27–29: again broaden PLGA ratio and MW windows while holding NMP and buprenorphine free base around ~300 mg and keeping SC once-per-month.
Interpretive takeaway: US 10,646,484 is not a single narrow formulation claim only. It has a nested claim architecture: a “headline” exact composition (claims 1/10/29) surrounded by broader variants (claims 4/8/9/24/27/28) that still require the same depot concept: buprenorphine free base + PLGA copolymer + NMP at specific weight fractions and PLGA MW/type boundaries.
When does exclusivity end for products covered by US 10,646,484?
Answer requires the listed FDA product and Orange Book patent listing(s). The claim text supplied does not include:
- the associated FDA application,
- listed Orange Book expiration date,
- regulatory exclusivity triggering events,
- or any tether to a named product.
No complete exclusivity timeline can be produced from the information provided.
What patents protect once-monthly subcutaneous buprenorphine depots like US 10,646,484?
US 10,646,484 itself is a method-of-use patent with composition limitations. Its protection scope is method claims that require practicing the specified formulation and administration regimen.
For a practical landscape view, method claims like these usually sit alongside at least three other patent categories in the same asset family:
- Drug product/formulation patents (same depot, different compositions and loading/excipients; sometimes different solvents or polymer types).
- Process/manufacturing patents (polymer microparticle manufacture, solvent removal, sterilization, scale-up, and depot assembly).
- Regimen and dosing schedule patents (monthly vs weekly, at least x months, induction rules, and continuation after stabilization).
However, a quantified “how many patents cover” analysis for this specific US 10,646,484 requires bibliographic extraction from USPTO/assignment and Orange Book listing crosswalks. Those data are not present in the prompt.
Which companies are challenging or would likely challenge US 10,646,484?
No defensible identification can be produced from the claim text alone. Determining challengers requires:
- Orange Book ANDA/505(b)(2) history,
- Paragraph IV filings,
- litigation dockets,
- or settlement announcements.
None of this is contained in the provided material.
What formulations are protected by US 10,646,484 (PLGA + NMP + buprenorphine free base)?
US 10,646,484 protection is defined by a three-component depot composition plus a monthly SC regimen.
Formulation elements and ranges (as claimed)
Fixed anchor elements:
- Buprenorphine free base: ~300 mg per composition dose.
- Vehicle/solvent: N-methyl-2-pyrrolidone (NMP) at large weight fractions (commonly ~50 wt% in the tightest claims).
Polymer element:
- PLGA copolymer:
- lactide:glycolide ratio: explicitly 50:50 in claims 1/10; broadened to 50:50 to 95:5 in other dependents.
- polymer end group: claim 1/10 require carboxy terminal group.
- molecular weight:
- tight claims: ~9,000–19,000 Da
- broader claims: windows like ~5,000–40,000 Da and ~5,000–30,000 Da.
wt% composition coupling:
- In the tightest claim family, the wt% triad is:
- buprenorphine at 18 wt%,
- PLGA at 32 wt%,
- NMP at 50 wt%.
In broader dependents, the wt% bands widen (buprenorphine as low as ~10 wt% up to ~30 wt% depending on the claim; PLGA from ~10 wt% to ~60 wt%; NMP from ~30 wt% to ~70 wt%).
Design-around pathways implied by the claim text
A competitor could attempt to avoid infringement by altering:
- buprenorphine form (free base vs alternative salt form or complexation), if not literally “free base” in the accused product,
- monthly SC regimen (e.g., different interval or route),
- polymer identity (exclude carboxy-terminated PLGA if claim requires it, or shift MW outside asserted windows),
- polymer ratio (move lactide:glycolide out of recited band),
- NMP level (change wt% outside recited ranges).
Because the claims are composition-limited, simply changing dosing duration without changing formulation may not be sufficient; similarly, changing NMP or PLGA specifications may defeat the “composition” elements even if the clinical regimen is similar.
What endpoint language is claimed (abstinence, craving, withdrawal, illicit use)?
The claim set uses endpoint language that tracks common clinical trial endpoints for OUD:
- Abstinence: claim 3/12.
- Craving: claims 13 (reduce) and 14 (eliminate).
- Withdrawal symptoms: claims 15 (reduce) and 16 (eliminate).
- Illicit opioid use: claims 17 (reduce) and 18 (eliminate).
These are “method of treating” statements and, in practice, are commonly supported by clinical evidence in prosecution and/or litigation. The scope still remains tied to the administration and composition limitations in claim 4.
How does US 10,646,484 compare with other buprenorphine depot patent estates?
A comparative estate analysis requires identifying:
- the competing buprenorphine depot products,
- their corresponding Orange Book listings and patents,
- and their claim sets (composition vs method vs process).
The prompt does not provide the specific marketed product name, applicant, or related patents. A comparative claim-strength matrix cannot be constructed without those references.
What is the Orange Book status of US 10,646,484?
Cannot be determined from the provided information. Orange Book status depends on:
- the listed FDA NDA/ANDA/505(b)(2) application number,
- the patent number association,
- listed expiration date and pediatric exclusivity adjustments,
- and whether the patent is listed for drug product, method-of-use, or both.
No such Orange Book linkage is included.
What generic entry risks exist for products potentially covered by US 10,646,484?
No entry-risk assessment can be made from claim text alone. Paragraph IV risk is a function of:
- FDA approval status,
- existing ANDAs/505(b)(2) candidates,
- listed patent numbers for the referenced application,
- and the timing of generic application submissions and litigation.
None of these required data are present.
What patent litigation affects US 10,646,484?
No litigation history can be produced without docket and party information. Claim text is insufficient to identify:
- whether there are active/inactive cases,
- case numbers,
- asserted claims,
- claim construction outcomes,
- or settlements.
Key Takeaways
- US 10,646,484 is a method-of-treatment patent with explicit composition limitations for a once-per-month subcutaneous buprenorphine free base depot in injection-drug patients with moderate-to-severe OUD.
- The narrowest claims lock a specific triad: ~300 mg buprenorphine free base (~18 wt%) + 50:50 carboxy-terminated PLGA (~32 wt%) at ~9,000–19,000 Da + NMP (~50 wt%), administered SC once monthly for ≥6 months (and in dependents ≥12 months).
- Broader dependents expand PLGA ratios and molecular weights while retaining the same overall depot concept (PLGA + NMP with defined wt% bands) and the once-monthly SC regimen.
- Endpoint-focused dependents (abstinence, craving, withdrawal, illicit use) add clinical specificity but do not remove the rigid dependence on the formulation and dosing structure.
FAQs
- Does US 10,646,484 require buprenorphine to be in free base form for infringement?
- Can changing PLGA lactide:glycolide ratio avoid coverage under the broader dependent claims?
- If dosing is subcutaneous once per month but for less than six months, does US 10,646,484 still apply?
- Do the endpoint claims (craving/withdrawal/illicit use) expand scope beyond the same formulation requirements?
- Is the carboxy-terminated PLGA requirement limited to specific dependent claims or present in all claim paths?
References (APA)
- United States Patent No. 10,646,484. (Provided claim text in prompt).
More… ↓
⤷ Start Trial
|
